Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT
AbstractBackground and Aims. Icosapent ethyl lowers triglycerides and significantly reduces major adverse cardiovascular events (MACE), though treatment ef